Large-Scale Trial Of Experimental Ebola Vaccine Begins In Liberia

Associated Press: Ebola vaccines trial starts in Liberia
“A large-scale human trial of two potential Ebola vaccines got under way in Liberia’s capital Monday, part of a global effort to prevent a repeat of the epidemic that has now claimed nearly 9,000 lives in West Africa…” (Paye-Layleh, 2/2).

International Business Times: Ebola vaccine trials on 30,000 volunteers to begin in Liberia
“…Scientists will give the vaccine to some 30,000 volunteers in a bid to put a halt to the ever increasing number of people who have already lost their lives to the virus. Over 8,500 people have succumbed to the disease already…” (Martin, 2/2).

TIME: The First Ever Large-Scale Ebola Vaccine Trial Begins in Liberia
“…British pharmaceutical and health care company GlaxoSmithKline developed the vaccine alongside the U.S. National Institutes of Health; should the trial be successful, it would be the first preventative vaccine against the killer virus…” (Regan, 2/2).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.